NCT05723549

A Study to Evaluate the PK, Safety and Tolerability of HCP1803.

A Randomized, Open-label, Single-Dose, Parallel Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1803 in Healthy Male Volunteers.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: Male
• Age: 19 Years – 45 Years
• Healthy volunteers: Accepted

Summary

A randomized, open-label, single-dose parallel study to evaluate the pharmacokinetics, safety and tolerability of HCP1803 in healthy male volunteers.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	HCP1803-3	Take it once per period
DRUG	RLD2002	Take it once per period
DRUG	HCP1904-1	Take it once per period

Timeline

• Start date: 2023-02-02
• Primary completion: 2023-03-20
• Completion: 2023-03-20
• First posted: 2023-02-10
• Last updated: 2023-09-22

Locations

1 site across 1 country: South Korea